论文部分内容阅读
目的 :观察联合应用恩丹思酮预防化疗呕吐反应疗效。方法 :采用自身对照法 ,5 5例化疗病人(34例含顺铂 )第 1周期单药组单用恩丹思酮 8mg ,化疗前 15～ 2 0min静推 ,化疗当天使用 ;第 2周期联合组联合应用甲氧氯普胺、地塞米松、恩丹思酮。恩丹思酮用法同上 ,甲氧氯普胺 10mg、地塞米松 5mg化疗前 15～ 2 0min静推 ,第 1～ 5天。结果 :含顺铂方案化疗病例中 ,联合组第 1～ 3天恶心控制率 (97 1% ,88 2 % ,91 2 % )均高于单药组 (82 3% ,82 3% ,5 2 9% ) ,且第 1天二者具有明显区别 ;联合组 1～ 3天呕吐控制率 (10 0 % ,10 0 % ,94 1% )均高于单药组 (10 0 % ,91 2 % ,79 4 % ) ,但二者差异不显著 ;在不含顺铂方案化疗病人中 ,联合组恶心、呕吐控制率稍高于单药组。不良反应主要为便秘、口干 ,未发生锥体外系反应。结论 :联合应用甲氧氯普胺、地塞米松、恩丹思酮可安全而有效地降低化疗引起的胃肠道反应 ,与单用恩丹思酮相比 ,疗效增加 ,且不会明显增加病人的经济负担
Objective: To observe the combined application of ondansetron to prevent chemotherapy and vomiting response. Methods: Fifty-five patients with chemotherapy (34 patients with cisplatin) were enrolled in this study. The patients in the first cycle were treated with Ondansetron 8 mg and were intravenously administered 15-20 min before chemotherapy. The second cycle of combination Combination of metoclopramide, dexamethasone, Ondansetron. Ondansetron usage ibid, metoclopramide 10mg, dexamethasone 5mg before chemotherapy 15 ~ 2 0min push, the first 1 to 5 days. Results: The nausea control rates (97 1%, 88 2%, 91 2%) in the combined group were higher than those in the single drug group (82.3%, 82.3%, 52 (10%, 100%, 94 1%) in the combined group were higher than those in the single drug group (10 0%, 91 2%, respectively) , 79 4%), but there was no significant difference between the two groups. In patients without cisplatin chemotherapy, the rate of nausea and vomiting in the combined group was slightly higher than that in the single drug group. Adverse reactions mainly constipation, dry mouth, no extrapyramidal reactions occurred. Conclusions: Combined use of metoclopramide, dexamethasone and ondansetron can reduce the gastrointestinal reaction induced by chemotherapy safely and effectively. Compared with enamine alone, the effect is not obvious Patient’s financial burden